William Seeds explains what is happening in his book Peptide Protocols Volume 1: [AOD-9604] is unable to induce dimerization and thereby activation of the receptor (no competition with HGH) This fragment holds the fat-reducing and tissue repair sequence and mimics the effect of HGH on lipid metabolism, without having growth-promoting or pro-diabetic effects [AOD-9604] inhibits lipoprotein lipase activity in adipose tissue, stimulating lipolysis in adipocytes Since AOD-9604 does not interact with growth hormone receptors, it means the peptide has the following advantages over HGH: Does not increase IGF-1 production Does not induce insulin resistance Does not stimulate muscle growth Since beta-3-adrenergic receptor activation appears to be a secondary mechanism of the AOD-9604 peptide, its primary and complete mechanism for fat mobilization and/or fat cell death within adipose tissue is not currently known
Most peptides are delivered through a small subcutaneous injection (similar to an insulin shot), which allows for fast and efficient absorption
A fascinating 2021 case report published in the BMJ Case Reports demonstrated the vital clinical importance of this pathway
Supervised care is not a marketing claim
By 104 weeks, approximately 77% of SELECT patients on dose were receiving the target semaglutide 2.4 mg weekly dose, which is lower than the corresponding proportion of patients in STEP 1 (89.6% were receiving the target dose at week 68) 14,21
I am passionate about helping women and prenatal clients in the Oklahoma City area, including Yukon, Edmond, and Moore, as this is a time when B12 needs are heightened
